Hepatic Safety and Antiretroviral Effectiveness in HIV-Infected Patients Receiving Naltrexone

Alcoholism: Clinical and Experimental Research

Volumn 36, Issue 2, 2012, Pages 318-324

  Tetrault, Jeanette M ^a   Tate, Janet P ^b,c   Mcginnis, Kathleen A ^b,d   Goulet, Joseph L ^a,b,c   Sullivan, Lynn E ^a   Bryant, Kendall ^e   Justice, Amy C ^a,b,c   Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Aging Cohort Study   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcoholism; HIV; Naltrexone; Opioid Related Disorders

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NALTREXONE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; ALANINE TRANSAMINASE; ALCOHOLISM; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG TOXICITY; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RNA, VIRAL; VETERANS;

HEPATITIS C VIRUS;

EID: 84856403200     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2011.01601.x     Document Type: Article

References (46)

1. Anton RF (2008) Naltrexone for the management of alcohol dependence. N Engl J Med359:715-721.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, Group CSR (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA295:2003-2017.
3. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE (2002) Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med17:377-381.
4. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL (1985) Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther38:419-422.
5. Berg BJ, Pettinati HM, Volpicelli JR (1996) A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf15:274-282.
6. Boppidi H, Daram SR (2008) Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med120:E01-E07.
7. Brahen LS, Capone TJ, Capone DM (1988) Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol28:64-70.
8. Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JFS, Justice AC (2005) A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res29:1190-1197.
9. Brewer C, Wong VS (2004) Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol9:81-87.
10. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD (1998) Self-reported antiretroviral therapy in injection drug users. JAMA280:544-546.
11. Centers for Disease Control and Prevention (2009) HIV/AIDS Surveillance Report. Available at: Accessed March 6, 2010.
12. Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, Lichtner M, Monforte ADA; Group ICS (2007) Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?AIDS21:599-606.
13. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry63:210-218.
14. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J (2001) Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med16:83-88.
15. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry54:1130-1135.
16. Diehl AM (2010) Hepatic complications of obesity. Gastroenterol Clin North Am39:57-68.
17. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology51:679-689.
18. Faragon JJ, Piliero PJ (2003) Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read13:433-434.
19. Fultz SL, Skanderson M, Mole LA, Gandhi N, Bryant K, Crystal S, Justice AC (2006) Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care44(8 Suppl 2):S25-S30.
20. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, Longshore D, Morton SC, Orlando M, Shapiro M (2002) The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol63:179-186.
21. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. [Erratum appears in JAMA. 2005 Jun 15:293(23):2864].[Erratum appears in JAMA. 2005 Apr 27;293(16):1978]. JAMA293:1617-1625.
22. Gekker G, Lokensgard JR, Peterson PK (2001) Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend64:257-263.
23. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR (2006) Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res30:860-865.
24. Hulse GK, Morris N, Arnold-Reed D, Tait RJ (2009) Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry66:1108-1115.
25. Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP (2006) Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol29:77-79.
26. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol29:350-357.
27. Lozano Polo JL, Gutierrez Mora E, Martinez Perez V, Santamaria Gutierrez J, Vada Sanchez J, Vallejo Correas JA (1997) [Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection]. Rev Clin Esp197:479-483.
28. Lucas GM, Cheever LW, Chaisson RE, Moore RD (2001) Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr27:251-259.
29. Lucas GM, Gebo KA, Chaisson RE, Moore RD (2002) Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS16:767-774.
30. Lucey MR, Silverman BL, Illeperuma A, O'Brien CP (2008) Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res32:498-504.
31. Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C (1985) A controlled trial of naltrexone in obese humans. Int J Obes9:347-353.
32. Marrazzi MA, Wroblewski JM, Kinzie J, Luby ED (1997) High-dose naltrexone and liver function safety. Am J Addict6:21-29.
33. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P (2001) Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict10:296-307.
34. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2006) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev (1):CD001333.
35. O'Malley SS (1996) Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol31(Suppl 1):77-81.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, pp 1-166. Available at: Accessed June 26, 2011.
37. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE (1986) Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr67:66-72.
38. Pini LA, Ferretti C, Trenti T, Ferrari A, Sternieri E (1991) Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metabol Drug Interact9:161-174.
39. Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA (2003) Alcohol consumption and HIV disease progression: are they related?Alcohol Clin Exp Res27:862-867.
40. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA (2004) Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses20:151-155.
41. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E (1997) Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol26:1-5.
42. Stein MD, Rich JD, Maksad J, Chen MH, Hu P, Sobota M, Clarke J (2000) Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse26:195-205.
43. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol36:544-552.
44. Sulkowski MS, Mast EE, Seeff LB, Thomas DL (2000) Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis30(Suppl 1):S77-S84.
45. Wang X, Douglas SD, Peng J-S, Metzger DS, O'Brien CP, Zhang T, Ho W-Z (2006) Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol79:1166-1172.
46. Yen M-H, Ko H-C, Tang F-I, Lu R-B, Hong J-S (2006) Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol38:117-120.